Advertisement
Australia markets close in 4 hours 1 minute
  • ALL ORDS

    7,785.10
    -113.80 (-1.44%)
     
  • ASX 200

    7,530.00
    -112.10 (-1.47%)
     
  • AUD/USD

    0.6370
    -0.0056 (-0.87%)
     
  • OIL

    85.36
    +2.63 (+3.18%)
     
  • GOLD

    2,427.60
    +29.60 (+1.23%)
     
  • Bitcoin AUD

    95,396.78
    -1,616.42 (-1.67%)
     
  • CMC Crypto 200

    1,265.22
    +379.69 (+40.75%)
     
  • AUD/EUR

    0.6000
    -0.0031 (-0.51%)
     
  • AUD/NZD

    1.0868
    -0.0007 (-0.07%)
     
  • NZX 50

    11,761.98
    -74.06 (-0.63%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,837.40
    +67.38 (+0.38%)
     
  • Hang Seng

    16,226.19
    -159.68 (-0.97%)
     
  • NIKKEI 225

    36,934.15
    -1,145.55 (-3.01%)
     

Moore Kuehn Encourages MTSC, SPRQ, NEOS, and PRSP Investors to Contact Law Firm

NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:

  • MTS Systems Corporation (NASDAQ: MTSC)

A proxy was recently filed with the SEC regarding Amphenol’s acquisition of MTS Systems. Under the proposed transaction, shareholders of MTS will receive $58.50 per share. The investigation concerns whether MTS’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price.

  • Spartan Acquisition Corp. II (NYSE: SPRQ)

ADVERTISEMENT

Spartan Acquisition has agreed to merge with Sunlight Financial. Under the proposed transaction, shareholders of Spartan Acquisition will retain only 26% of the combined company.

  • Neos Therapeutics, Inc. (NASDAQ: NEOS)

A registration statement was recently filed with the SEC regarding Aytu BioScience’s acquisition of Neos Therapeutics. Under the proposed transaction, shareholders of Neos will receive 0.1088 shares of Aytu common stock per share. The registration statement may omit material information regarding the financial metrics and analyses used to evaluate the merger.

  • Perspecta Inc. (NYSE: PRSP)

Perspecta has agreed to be acquired by affiliates of Peraton. Under the proposed transaction, shareholders of Perspecta will receive $29.35 i per share.

Moore Kuehn is investigating whether the Boards of the above companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process.

Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245. The consultation and case are free with no obligation to you. Moore Kuehn pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Moore Kuehn is a 5-star Google rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims. For additional information about Moore Kuehn, please visit http://www.moorekuehn.com/practice/new-york-securities-litigation/.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Moore Kuehn, PLLC
Justin Kuehn, Esq.
30 Wall Street, 8th Floor
New York, New York 10005
jkuehn@moorekuehn.com
(212) 709-8245